The significance of heregulin in breast cancer tumor progression and drug resistance

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 57-66

  Lupu, R ^a   Cardillo, M ^a   Cho, C ^a   Harris, L ^a   Hijazi, M ^a   Perez, C ^a   Rosenberg, K ^a   Yang, D ^a   Tang, C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Differentiation; Drug resistance; EGF receptor family; erbB 2; erbB 4; Estrogen dependence; Heregulin; Invasiveness; Prognosis; Proliferation

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ERB B2 RECEPTOR; ESTROGEN; ETOPOSIDE; NEU DIFFERENTIATION FACTOR; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL GROWTH; CHEMOTAXIS; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; GENETIC ENGINEERING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; CELL DIVISION; DRUG RESISTANCE; FEMALE; GLYCOPROTEINS; HUMANS; NEOPLASM INVASIVENESS; NEUREGULINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFECTION;

EID: 0030033165     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803784     Document Type: Conference Paper

References (53)

1. Henderson I, Harris J, Kinne D, Hellman S: In: De Vita V, Hellman S (eds) Principles and Practice of Oncology. Lippincott, Philadelphia, 1989, pp 1197-1268
2. Schecter AL, Stern DF, Vaidyanathan L, Decker SJ: The neu oncogene: an erbB-related gene encoding a 185,000 Mr tumor antigen. Nature 312:513-516, 1984
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human BC: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
4. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: neu-protein over-expression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
5. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991
6. Nicholson S, Wright C, Sainsbury RC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811-814, 1990
7. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeberg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science 230:1132-1139, 1985
8. Fukushige SI, Matsubaru K, Yoshida M: Localization of a novel v-erbB-related gene, c-erbB-2, on chromosome 17 and its amplification in a gastric cell line. Mol Cell Biol 6:955-958, 1986
9. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986
10. Semba K, Kamata N, Toyoshima K, Yamamoto T: v-erbB related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Aci USA 82:6497-6501, 1985
11. Muller W, Sinn E, Patengale P, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988
12. Bouchard L, Lamarre L, Tremblay P, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931-936, 1989
13. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182, 1986
14. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185 (HER2) causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci USA 84: 7159-7163, 1987
15. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger, Lippman ME, King CR: Pathological findings from National Surgical Adjuvant Breast Project (protocol B-06), prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
16. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Home CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
17. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1988
18. Shih C, Padhy L, Murray M, Weinberg RA: Transforming genes of carcinoma and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264, 1981
19. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986
20. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA: Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570-5574, 1988
21. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against c-erbB-2 protein enhances the cytotoxicity of cis-diammine dichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
22. Wiltschke C, Tyl E, Steininger A, Zielinski C, Spona J, Zeilinger R, Kury F, Czerwenka K, Kubista E, Speiser P, Preis P: Increased NK-cell activity correlates with low or negative expression of the HER-2/neu oncogene in breast cancer patients. Proc AACR 32:203, 1991
23. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990
24. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human.breast cancer cells. Oncogene 5:1001-1006, 1990
25. Lupu R, Wellstein A, Sheridan J, Ennis BW, Zugmaier G, Katz D, Lippman ME, Dickson RB: Purification and characterization of a novel growth factor from human breast cancer cells. Biochem 31:7330-7340, 1992
26. erbB-2 Science 249:1552-1555, 1990
27. erbB-4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750, 1993
28. erbB-4. Nature 366:473-475, 1993
29. Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 89:2287-2291, 1992
30. Lupu R, Lippman ME: The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27:83-93, 1993
31. Huang SS, Huang JS: Purification and characterization of the neu/erbB2 ligand-growth factor from bovine kidney. J Biol Chem 267:11508-11512, 1992
32. Wen D, Peles E, Cupples R, Suggs SV, Bacus S, Lou Y, Trail G, Hu S, Silbiger SM, Ben Levi R, Koski R, Lu HS, Yarden Y: Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559-572, 1992
33. erbB2. Science 256:1205-1210, 1992
34. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelman EP, Byers SW: Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differentiation 2:365-372, 1991
35. Staebler A, Sommers C, Mueller SC, Bayers S, Thompson EW, Lupu R: Modulation of breast cancer progression and differentiation by the gp30/heregulin. Breast Cancer Res Treat 31:175-182, 1994
36. Hijazi MM, Mueller SC, Torri J, Coopman P, Lupu R, Thompson EW: Gp30/Heregulin promotes invasive behavior and phenotype in SKBR3 cells and is blocked by gp30 polyclonal antiserum. Clinical & Experimental Metastasis, Vol 12, 5th Int Congress MRS, Abstract 69, 1994
37. Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman ME, Lupu R: A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differentiation 3:401-411, 1992
38. Muss HB, Thor A, Berry DA, Kute T, et al: erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 5:1260-1266, 1994
39. Allred DC, Clark GM, Tandon AK, Molina R, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992
40. Gusterson BA, Gelber RD, Goldhirsh A, Price KN, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
41. Matsumura K, Isola J, Chew K, Henderson C, Smith HS, Harris AL, Hickson ID, Waldman F: Topoisomerase II alpha deletion as well as amplification associated with erbB-2 amplification in breast cancer. Proc AACR 35:454, 1994
42. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL: Topoisomerase JI alpha co-amplification with erbB-2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938, 1993
43. Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K: Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Research 11:429-431, 1991
44. Lemoine NR, Sikora K: Interventional genetics and cancer treatment. Brit Med J 306:6390-6393, 1993
45. Tang C, Cardillo M, Yang D, Cho C, Waibel C, Perez C, Lupu R: Heregulin β2 isoform can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Proc AACR 36:169, 1995
46. Tang C, Perez C, Grunt T, Lupu R: Biological characterization of an erbB-2 ligand: involvement of human breast cancer from a hormone dependent to hormone independent phenotype. Proc AACR 35:36, 1994
47. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Research 47:3239-3245, 1987
48. Hijazi MM, Lupu R: Heregulin/gp30 polyclonal antibody inhibits invasive behavior in MDA-MB-231 breast cancer cells. Proc AACR 36:75, 1995
49. Tryggvason K: Patterns of basement degradation by metastatic tumor cell enzymes. In: Lapis K, Liotta LA, Rabson AS (eds) Biochemistry and Molecular Genetics of Cancer Metastasis. Martinus Nijhoff Publ, Boston, pp 151-163
50. Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624-6629, 1992
51. Cardillo M, Tang C, Lupu R: Heregulin induces a metastatic phenotype to breast cancer cells in vivo. Proc AACR 36:262, 1995
52. Harris LN, Tang C, Yang D, Lupu R: Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin. Proc AACR 36:426, 1995
53. Harris LN, Tang C, Perez C, Lupu R: Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with gp-30 (heregulin), an activator of the erbB-2/erbB-4 signalling pathway. Fifth Meeting on the Molecular Basis of Cancer, June 1994